pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·2h ago·1 min read
save

Beam Therapeutics sues Chinese scientists and firms YolTech, Serapha Bio over alleged gene-editing technology theft

Sep 29, 2026·read at Endpoints ↗Negative

Beam Therapeutics, a Cambridge-based company developing CRISPR base editing therapies, has filed a lawsuit.

The suit names two Chinese scientists and the biotech firms YolTech and Serapha Bio, accusing them of misappropriating Beam’s trade secrets.

Beam alleges the defendants copied its proprietary gene-editing technology and used it without permission.

The complaint seeks legal remedies for the alleged theft, underscoring growing tensions over intellectual property in the rapidly evolving gene-editing field.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Beam sues YolTech and Serapha Bio for allegedly stealing its gene editing tech”

read at Endpoints ↗
88 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Beam Therapeutics Inc.8
topics
CRISPR/Cas94Base Editing2

related stories

  • 3h agoBeam sues 2 biotechs, alleging theft of base editing trade secretsBioPharma Dive
  • Jul 28STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATDSTAT
  • Jul 8Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversalBioPharma Dive
  • Sep 14Cellectis quits CAR-T and pivots to ‘in vivo’ gene editingBioPharma Dive
  • Sep 14Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagonFierce Biotech